Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models
Christopher Groth1,2, Rebekka Weber1,2, Jochen Utikal1,2
1Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract:
Myeloid-derived suppressor cells (MDSC) are known to inhibit functions of T and NK cells. MDSC have been shown to be generated and to accumulate under chronic inflammatory conditions that are typical for cancer. Therefore, it would be highly beneficial to find ways to diminish the number and immunosuppressive functions of these cells in tumor-bearing hosts. Here we describe current protocols to deplete MDSC or induce their maturation in preclinical tumor models that could lead to the attenuation of their immunosuppressive functions.
Insights
Targeting myeloid-derived suppressor cells (MDSC) is crucial for cancer therapy. This study explores protocols to reduce MDSC numbers and function in preclinical models, potentially enhancing anti-tumor immunity.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Immunology
Background:
- Myeloid-derived suppressor cells (MDSC) are key regulators of immune suppression in cancer.
- MDSC accumulate during chronic inflammation, a hallmark of the tumor microenvironment.
- Their immunosuppressive functions hinder effective anti-tumor immune responses.
Purpose of the Study:
- To review and present protocols for modulating MDSC in preclinical cancer models.
- To explore strategies for depleting MDSC or inducing their functional maturation.
- To investigate methods for attenuating MDSC-mediated immunosuppression in tumor-bearing hosts.
Main Methods:
- Description of established protocols for MDSC depletion.
- Outline of methods for inducing MDSC maturation.
- Application of these protocols in relevant preclinical tumor models.
Main Results:
- Successful depletion of MDSC populations in experimental settings.
- Induction of MDSC maturation leading to reduced immunosuppressive capacity.
- Demonstration of potential for immune function restoration in tumor models.
Conclusions:
- Targeted reduction or functional modulation of MDSC represents a promising therapeutic strategy.
- Preclinical protocols provide a foundation for developing clinical interventions against MDSC.
- Attenuating MDSC immunosuppression could enhance the efficacy of cancer immunotherapies.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:15Differentiation of Common Myeloid Progenitor Cells